Participants 127 183 5
 patients with mixed dyslipidaemia and metabolic syndrom
Participants 582 627 4
e in patients with mixed dyslipidaemia and Me
Participants 651 1046 10
y randomised patients with low-density lipoprotein cholesterol (LDL-C) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day (R group, n = 30) or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day (RF group, n = 30) or ω-3 fatty acids 2 g/day (Rω group, n = 30). In the present study, only patients with MetS were included (24, 23 and 24 in the R, RF and Rω groups respe
